Suggested remit: To appraise the clinical and cost effectiveness of treprostinil sodium within its marketing authorisation for treating chronic thromboembolic pulmonary hypertension.
Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
Further information The NICE Topic Selection Oversight Panel (TSOP), met in August 2022 to carefully consider the suitability of this topic for a Technology Appraisal (TA). The panel concluded it would not be an efficient use of NHS resources to conduct an evaluation. The topic will be formally removed from the NICE work programme.
ID number 3926

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
09 November 2022 Topic selection. .
05 November 2021 - 03 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 December 2021 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of treprostinil sodium for treating symptomatic chronic thromboembolic pulmonary hypertension. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. Following an update from the company that markets treprostinil sodium, NICE will not be progressing with the scoping exercise at this time. The consultation on the draft scope will now close and the workshop arranged for Monday 20 December 2021 has been cancelled. Please accept our apologies for any inconvenience.

For further information on how we select topics for development, please see our page about topic selection